Vertex Pharmaceuticals (VRTX)
Add to Watchlists Create an Alert
78.35
-0.08 -0.10%
NASDAQ
May 23, 1:01PM
BATS Real time
Currency in USD
Vertex Pharmaceuticals Revenue Quarterly:
328.37M for Dec. 31, 2012Vertex Pharmaceuticals Historical Revenue Quarterly Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | 328.37M |
| Dec. 31, 2012 | 333.99M |
| Sept. 30, 2012 | 336.01M |
| June 30, 2012 | 418.30M |
| March 31, 2012 | 438.74M |
| Dec. 31, 2011 | 563.34M |
| Sept. 30, 2011 | 659.20M |
| June 30, 2011 | 114.42M |
| March 31, 2011 | 73.66M |
| Dec. 31, 2010 | 65.52M |
| Sept. 30, 2010 | 23.80M |
| June 30, 2010 | 31.62M |
| March 31, 2010 | 22.43M |
| Dec. 31, 2009 | 33.89M |
| Sept. 30, 2009 | 24.96M |
| June 30, 2009 | 19.06M |
| March 31, 2009 | 23.98M |
| Dec. 31, 2008 | 32.81M |
| Sept. 30, 2008 | 31.61M |
| June 30, 2008 | 69.41M |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
| Dec. 31, 2000 | Go Pro |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity. Increasing revenues over time are generally a good sign of company's growth.
While a bit obvious, if a lemonade company has sold 30 million in revenue and has 10 million in costs of goods sold, the company's revenue is still 30 million. (Expenses are not accounted in Revenue).
Learn More
VRTX Revenue Quarterly Benchmarks
| Companies | |
|---|---|
| Cleveland BioLabs | 2.162M |
| Gilead Sciences | 2.532B |
| Merck | 10.67B |
VRTX Revenue Quarterly Rankings
| Overall |
81st percentile 1514 of 8006 |
| Sector |
83rd percentile 112 of 686 in Healthcare |
| Industry |
95th percentile 10 of 248 in Biotechnology |
VRTX Revenue Quarterly Range, Past 5 Years
| Minimum | 19.06M | Jun 2009 |
| Maximum | 659.20M | Sep 2011 |
| Average | 182.26M |
